Pulmonary Function, Chronic Obstructive Pulmonary Disease (COPD) Prevalence, and Systemic Inflammation in Chronic Heart Failure With or Without COPD

1) Pulmonary Function in CHF; 2) COPD Prevalence, Underdiagnosis and Overdiagnosis in CHF Patients and Its Independent Predictors; 3) Are There Signs of Systemic Inflammation in CHF With or Without COPD?

The aim of the present study is:

1. To investigate pulmonary function abnormalities (restriction, obstruction, diffusion impairment, mixed pulmonary defects) in patients with chronic heart failure (CHF) and to determine which of these pulmonary abnormalities prevail and to what extent.
2. To determine the prevalence, underdiagnosis, and overdiagnosis of chronic obstructive pulmonary disease (COPD) as determined by spirometry and according to Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria in patients with CHF.
3. To investigate the presence of systemic inflammation, as measured by inflammatory parameters (leukocytes, platelets, high sensitivity CRP), in CHF patients with or without COPD.

Study Overview

• Status: Completed
• Conditions: Heart Failure; Inflammation; Pulmonary Disease, Chronic Obstructive
• Intervention / Treatment: Other: Pulmonary function tests; Other: Blood tests; Other: Questionnaires; Other: Chest radiograph

Detailed Description

1. The impact of chronic heart failure (CHF) on pulmonary function is incompletely understood and remains controversial. It is difficult to separate the contribution of stable CHF from underlying pulmonary disease and other confounding influences, such as changes due to normal ageing, obesity, environmental exposure (mainly smoking), stability of disease, a history of coronary artery bypass grafting, and other conditions that can lead to pulmonary function abnormalities. Studies have shown that isolated or combined pulmonary function impairment, such as diffusion impairment, restriction, and to a much lesser extent airway obstruction are common in patients with CHF and can contribute to the perception of dyspnoea and exercise intolerance. Pulmonary dysfunction increases with the severity of heart failure and provides important prognostic information. Most investigators compared pulmonary function in CHF patients with normal predicted values or control subjects. However, there is only a small body of literature addressing the prevalence of different pulmonary function abnormalities in patients with CHF. In addition, these studies have included (potential) heart transplant recipients, who represent one extreme of the heart failure spectrum. The aim of the present study was to investigate the prevalence of pulmonary function abnormalities in patients with CHF and to determine which of these pulmonary abnormalities prevail and to what extent.
2. Chronic obstructive pulmonary disease (COPD) frequently coexists with CHF, leading to impaired prognosis as well as diagnostic and therapeutic challenges. However, lung functional data on COPD prevalence in CHF are scarce and COPD remains widely undiagnosed or misdiagnosed. The reported prevalence rates of COPD range from 9 to 41% in European cohorts and from 11 to 52% in North American patients with heart failure. The purpose of this study was to determine the prevalence, underdiagnosis, and overdiagnosis of COPD as determined by spirometry and according to Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria in patients with CHF.
3. There is abundant evidence of increased systemic inflammation in both CHF and COPD and it is remarkable to observe the similarities of inflammation in both conditions. These inflammatory responses may provide a mechanistic bridge between COPD and cardiac co-morbidity. However, there is no information regarding systemic inflammation when CHF and COPD coexist. It is unknown whether the combination of these two diseases leads to increased systemic inflammation in comparison to CHF alone. The aim of this study was to investigate the presence of systemic inflammation, as measured by inflammatory parameters (leukocytes, platelets, high sensitivity CRP), in CHF patients with or without COPD.

• Study Type: Interventional
• Enrollment (Actual): 234
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Netherlands
  • Gelderland
    • Arnhem, Gelderland, Netherlands, 6800 TA
      • Rijnstate Hospital
    • Zevenaar, Gelderland, Netherlands, 6903 ZN
      • Rijnstate Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Chronic heart failure patients with left ventricular systolic dysfunction (left ventricular ejection fraction < 40%)
• Outpatients
• New York Heart Association (NYHA) class I-IV
• 18 years and older
• Informed consent

Exclusion Criteria:

• Patients who do not meet the inclusion criteria
• Patients who are not able to cooperate or undergo pulmonary function tests
• Other diseases that can lead to obstructive lung function: asthma, cystic fibrosis
• Malignancy with bad prognosis (survival < 6 months)
• Hospitalisation to the pulmonary department in the past 6 weeks, in this case patients will have the pulmonary function tests ≥ 6 weeks after discharge
• Patients who are already participating in another study within the cardiology department

Additional exclusion criteria for the first primary objective:

• Disorders/diseases that can lead to pulmonary function impairment:

  • Pulmonary: lung surgery (lobectomy/pneumectomy), parenchymal neoplasms, interstitial lung disease, sarcoidosis, pneumoconioses, lung abscess, lobar pneumonia, post- infectious scarring, atelectasis, radiation fibrosis
  • Pleural: diffuse pleural thickening, mesothelioma, pleural effusion not due to heart failure, pneumothorax
  • Neuromuscular diseases: ALS, poliomyelitis, myopathy, bilateral diaphragmatic paralysis, high spinal cord lesions, myasthenia gravis
  • Abdominal: obesity (BMI > 35) (exclusion only from the restriction prevalence analysis)
  • Pericardial: major pericardial effusion
  • Large mediastinal processes
  • Collagen vascular diseases

Additional exclusion criteria for the third primary objective:

• Active/recent infection
• Febrile or inflammatory disease such as rheumatoid arthritis
• Use of antibiotics or anti-inflammatory medication, such as etanercept, infliximab, systemic use of corticosteroids and NSAID's other than acetylsalicylic acid
• Malignancy
• Auto-immune disease
• Collagenvascular disease
• Gastro-intestinal disease (such as inflammatory bowel disease)
• Recent operation (past 3 months)
• Renal or liver failure
• Thyroid disease
• Obstructive sleep apnoea syndrome (OSAS)
• Disorders that lead to thrombocytopenia/leukocytopenia or thrombocytosis/leukocytosis (hs-CRP analysis will take place in case these disorders do not affect hs-CRP)

Study Plan

How is the study designed?

Design Details

• Primary Purpose: DIAGNOSTIC
• Allocation: NA
• Interventional Model: SINGLE_GROUP
• Masking: NONE

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Pulmonary function abnormalities	Restriction, obstruction, diffusion impairment, mixed pulmonary defects	1 day
COPD prevalence, underdiagnosis, and overdiagnosis	Patients with newly diagnosed COPD repeated spirometry after 3 months of standard treatment for COPD to confirm persistent airway obstruction (COPD) and thus exclude asthma.	3 months
Systemic inflammation	Leukocytes, platelets, high sensitivity CRP.	1 day

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Quality of life	Minnesota Living with Heart Failure Questionnaire (MLHFQ), on the day of initial pulmonary function tests and 3 months later.	3 months
Dyspnoea	modified Medical Research Council (MRC) dyspnea scale and 10-point Borg dyspnoea score, on the day of initial pulmonary function tests and 3 months later.	3 months
Independent predictors of COPD	Patients characterisitcs, such as age, gender, body mass index, symptoms, smoking history, family history, and so on.	3 months

Collaborators and Investigators

• Sponsor: Rijnstate Hospital
• Collaborators: GlaxoSmithKline
• Investigators: Principal Investigator: Armine G Minasian, MD, Rijnstate Hospital, Arnhem, The Netherlands

Publications and helpful links

General Publications

• Minasian AG, van den Elshout FJ, Dekhuijzen PN, Vos PJ, Willems FF, van den Bergh PJ, Heijdra YF. Using the Lower Limit of Normal Instead of the Conventional Cutoff Values to Define Predictors of Pulmonary Function Impairment in Subjects With Chronic Heart Failure. Respir Care. 2016 Feb;61(2):173-83. doi: 10.4187/respcare.04101. Epub 2015 Oct 20.
• Minasian AG, van den Elshout FJ, Dekhuijzen PR, Vos PJ, Willems FF, van den Bergh PJ, Heijdra YF. Serial pulmonary function tests to diagnose COPD in chronic heart failure. Transl Respir Med. 2014 Dec;2(1):12. doi: 10.1186/s40247-014-0012-5. Epub 2014 Sep 25.

Study record dates

Study Major Dates

• Study Start: October 1, 2009
• Primary Completion (ACTUAL): April 1, 2011
• Study Completion (ACTUAL): June 1, 2011

Study Registration Dates

• First Submitted: September 2, 2011
• First Submitted That Met QC Criteria: September 6, 2011
• First Posted (ESTIMATE): September 7, 2011

Study Record Updates

• Last Update Posted (ESTIMATE): September 7, 2011
• Last Update Submitted That Met QC Criteria: September 6, 2011
• Last Verified: September 1, 2011

More Information

Terms related to this study

• Keywords: Prevalence; Systemic inflammation; Chronic obstructive pulmonary disease (COPD); Airway obstruction; Chronic heart failure; Restriction; Pulmonary function tests; Overdiagnosis; Pulmonary function abnormalities/impairment; Diffusion impairment; Underdiagnosis; Diagnostic Errors
• Additional Relevant MeSH Terms: Pathologic Processes; Heart Diseases; Cardiovascular Diseases; Respiratory Tract Diseases; Lung Diseases, Obstructive; Heart Failure; Lung Diseases; Pulmonary Disease, Chronic Obstructive; Inflammation
• Other Study ID Numbers: LTC-607-070409